Immunosuppression in inflammatory bowel disease: how much is too much?
Immunosuppression in inflammatory bowel disease: how much is too much?
复制标题
炎症性肠病的免疫抑制：多少才算太多？
DOI：
10.1097/mog.0b013e328354567f
复制
发表时间：
2012
影响因子：
2.5
通讯作者：
Colombel,Jean-Frédéric
中科院分区：
文献类型：
--
作者：
Cohen,BenjaminL;Torres,Joana;Colombel,Jean-Frédéric
在这篇综述中，我们的目的是讨论一些与使用免疫抑制药物治疗炎症性肠病相关的安全性问题，以及降级或停止治疗的可能策略。最终，选择停用抗肿瘤坏死因子或免疫调节剂是根据估计的风险-效益比根据具体情况做出的决定。除了已确定的停药后复发的预测因素外，其他考虑因素，如长期安全性、成本和疾病的自然史也必须纳入讨论。
In this review we aim to discuss some of the safety concerns related to the use of immunosuppressive drugs used in inflammatory bowel disease, as well as the possible strategy for de-escalation or discontinuation therapy. Eventually, choosing to stop either the anti-TNF or the immunomodulator is a case-by-case decision based on the estimated risk–benefit ratio. In addition to the identified predictors of relapse after therapy discontinuation, other considerations such as long-term safety, cost, and natural history of the disease must be brought into this discussion.